NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Core Insights - NuCana plc announced the discontinuation of the NuTide:323 study based on a pre-planned initial analysis, indicating that the combination of NUC-3373 with other agents was unlikely to meet its primary objective of superior Progression Free Survival compared to the control arm [1][2] - Despite the setback with NuTide:323, ongoing studies NuTide:701 and NuTide:303 continue, with promising data on NUC-7738 plus pembrolizumab to be presented at the ESMO Annual Conference in September 2024 [1][2] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which aims to enhance the efficacy and safety of nucleoside analogs [3] - The company's pipeline includes NUC-3373, derived from 5-fluorouracil, and NUC-7738, a novel agent targeting multiple aspects of the tumor microenvironment [3] Study Details - The NuTide:323 study aimed to develop NUC-3373 as a replacement for 5-FU in combination with other agents for second-line colorectal cancer treatment, but the results were disappointing [2] - The ongoing NuTide:303 study evaluates NUC-3373 in combination with pembrolizumab for advanced solid tumors and docetaxel for lung cancer [3]